Working… Menu
Help guide our efforts to modernize
Send us your comments by March 14, 2020.

Effects of Tetrahydrobiopterin on Blood Pressure

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00208780
Recruitment Status : Completed
First Posted : September 21, 2005
Last Update Posted : November 18, 2013
American Heart Association
Information provided by (Responsible Party):
Arshed A. Quyyumi, Emory University

Brief Summary:
Tetrahydrobiopterin (BH4) is a cofactor for the nitric oxide (NO) synthase enzymes, such that its insufficiency results in uncoupling of the enzyme, leading to release of superoxide rather than NO in disease states, including hypertension. We hypothesized that oral BH4 will reduce arterial blood pressure (BP) and improve endothelial function in hypertensive subjects. Oral BH4 was given to subjects with poorly controlled hypertension (BP >135/85 mm Hg) and weekly measurements of BP and endothelial function made. In Study 1, 5 or 10 mg kg−1 day−1 of BH4 (n=8) was administered orally for 8 weeks, and in Study 2, 200 and 400 mg of BH4 (n=16) was given in divided doses for 4 weeks

Condition or disease Intervention/treatment Phase
Hypertension Drug: Tetrahydrobiopterin Early Phase 1

Show Show detailed description

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 24 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Effects of Tetrahydrobiopterin on Blood Pressure
Study Start Date : December 2004
Actual Primary Completion Date : December 2005
Actual Study Completion Date : December 2005

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Dose-response of oral BH4
Eight subjects received 100 mg of oral BH4 twice a day and 8 received 200 mg twice daily.
Drug: Tetrahydrobiopterin
Experimental: Onset & duration of action of oral BH4
Eight hypertensive subjects were assigned to either 5 mg kg−1 day−1 (n=4) or 10 mg kg−1 day−1 (n=4) of BH4, given in two divided doses orally for 8 weeks.
Drug: Tetrahydrobiopterin

Primary Outcome Measures :
  1. Evaluate the effects of BH4 on BP

Secondary Outcome Measures :
  1. Evaluate the effects of BH4 on vascular function

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Male or female patients without childbearing potential between the ages of 18 and 75 years
  2. History of documented essential hypertension or newly diagnosed hypertension (BP >140 mmHg systolic and/or 90 mmHg diastolic measured on 2 separate occasions)
  3. Patients on conventional anti-hypertensive therapy with poorly controlled hypertension (BP >135/85 mmHg). Their anti-hypertensive regimen will remain unchanged throughout the study period. Patients will not need to stop taking their prescribed anti-hypertensives.
  4. Controls will be recruited for part 2 of the study. These will be patients who meet the age and childbearing criteria above, who have no history of hypertension, arterial BP of <130 systolic and <85 diastolic, no evidence of diabetes mellitus, total cholesterol <240 and be non-smoking for at least six months.
  5. Patients can be at any stage of hypertension. They can be at any performance status. The only requirement will be that they be able to come to scheduled follow up visits either by themselves or with assistance. Patients will need to be able to give informed consent.

Exclusion Criteria:

  1. Female subjects with childbearing potential.
  2. History of symptomatic coronary or peripheral vascular disease.
  3. Known secondary causes for hypertension
  4. Severe uncontrolled hypertension (BP >180 mmHg systolic and /or 110 mmHg diastolic).
  5. Severe co-morbid conditions which would limit life expectancy to less than 6 months.
  6. Patients unable to give informed consent or adhere to the protocol.
  7. Patients participating in another study protocol.
  8. Patients with organ failure, creatinine >2.5 mg/dL or hepatic enzymes >2X normal
  9. Recent (within 6 weeks) alteration of any concomitant therapy.
  10. Presence of intercurrent illness
  11. Bleeding disorders

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00208780

Layout table for location information
United States, Georgia
Emory University
Atlanta, Georgia, United States, 30322
Sponsors and Collaborators
Emory University
American Heart Association
Layout table for investigator information
Principal Investigator: Arshed A Quyyumi, MD Emory University

Publications of Results:
Layout table for additonal information
Responsible Party: Arshed A. Quyyumi, Professor, Emory University Identifier: NCT00208780    
Other Study ID Numbers: 0476-2004
First Posted: September 21, 2005    Key Record Dates
Last Update Posted: November 18, 2013
Last Verified: November 2013
Keywords provided by Arshed A. Quyyumi, Emory University:
Oxidative Stress
Additional relevant MeSH terms:
Layout table for MeSH terms
Vascular Diseases
Cardiovascular Diseases